中文 English

Jiangli Zhang, CEO of Singlera Genomics, participates in a roundtable discussion at Huaxing Capital Healthcare and Life Sciences Summit

The future of cancer precision medicine
October 28, 2016 – Shanghai, China
Top CEOs and investors in the medical, life science and technology industries from China and the United States gathered for the Huaxing Capital Healthcare and Life Sciences Summit held October 27-28, 2016 in Shanghai, China. The Summit theme was “Advancing towards an international market and embracing innovation.” Topics discussed during the Summit focused on the status quo and development of China's life sciences industry, cutting-edge technologies in the pharmaceutical, biotechnology and medical devices industries, the future of technology, and developing trends.
Jiangli Zhang, co-founder and CEO of Singlera Genomics, Inc., participated in a roundtable discussion on in-vitro diagnosis, hosted by China Renaissance Company. The roundtable also included Qing Tan, Managing Partner at CDBI Partners, Shaoren Zhang, COO of Yikang Genomics Company, Zhigang Wu, COO of Burning Rock Dx, Kang Ying, CEO of Accuragen, and Danyi Wen, CEO of LIDE Biotech. The discussion focused on the future market development of cancer diagnostics in China.
Jiangli Zhang discussed his experience with the development and marketing of next-generation sequencing (NGS) products and mentioned cutting-edge technologies and bottlenecks in the development of cancer diagnostics. He discussed why cancer precision medicine with NGS as a technology platform has a bright future. He also emphasized that cancer detection from liquid biopsy and tissue samples are complementary to each other. He mentioned that although liquid biopsy is an emerging field, the rapid evolution and competition in the industry and the capacity for continuous technological innovation will serve as the competitive edge of any enterprise's long-term growth.
Jiangli Zhang was honored with the Annual CEO Award in China by the United Nations Industrial Development Organization (UNIDO). Previously, he served as VP/GM of ThermoFisher Scientific Healthcare Solutions China and Gene Company Ltd. where he introduced multiple advanced molecular diagnostic techniques in China, including an immunohistochemical product manufactured by Dako, FISH products from Abbott, nucleic acid detection products from Qiagen, and gene chip products from Affymatrix. He also co-founded and was COO of the leading website in life sciences in China, www.ebiotrade.com.

返 回